Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Peter Impey

- PMLiVE

AZ’s COVID-19 vaccine proves promising in elderly participants, new data shows

Immune responses were similar in younger and older adults

Sanofi reception

Sanofi’s quadrivalent flu vaccine Supemtek scores EU approval

Company expects first EU launches in 2022/2023 flu season

- PMLiVE

Not waving but drowning – reflections on data curation in the age of information overload

By Brian Parsons

- PMLiVE

MSD launches antibiotic combo Recarbrio in UK

Therapeutic indicated to treat infections caused by Gram-negative bacteria

- PMLiVE

Pfizer, BioNTech’s COVID-19 vaccine is 95% effective, final analysis shows

Vaccine is over 94% effective in adults over 65 years of age

- PMLiVE

FDA set to publish reviews of data relating to COVID-19 vaccine EUAs

Agency set to publish data as part of 'transparency' efforts

- PMLiVE

Sinovac’s COVID-19 vaccine produces antibody response in mid-stage study

Level of antibodies in vaccinated group lower than recovered COVID-19 patients

- PMLiVE

OPEN Health Group Appoints New Leadership

OPEN Health Group today announced that Rob Barker has been appointed Chief Executive Officer. Rob succeeds outgoing CEO and Co-Founder, David Rowley, who is stepping down after 10 years. A...

OPEN Health

- PMLiVE

The human connection: how to achieve emotive creativity in pharma

By Ian Ray

Roche Basel Switzerland

Roche’s flu pill Xofluza moves closer towards EU approval

CHMP recommends drug for approval in the EU

- PMLiVE

EU secures 405 million doses of CureVac’s COVID-19 vaccine

CureVac revealed early stage data for its vaccine earlier this month

- PMLiVE

J&J advances COVID-19 vaccine into second phase 3 trial

ENSEMBLE study will enrol 60,000 people worldwide

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links